Development of multispecific assemblies of Nanofitins with anti-tumor activities @ the 8th Antibody Industrial Symposium 2020

Digital, November 2020

Affilogic is developing a new anti-cancer therapeutic approach. Different multispecific assemblies of Nanofitins are developed with a variation of the modules that compose them. In order to potentiate the anti-tumor response, the choice of Nanofitin modules to assemble focuses on those with activities involved in cancer synergistic signaling pathways. Read more

This project was partially sponsored from January 2018 to December 2020 by a grant from the European Regional Development Fund (ERDF / FEDER) via the Region Pays de Loire.

Development of multispecific assemblies of Nanofitins with anti-tumor activities

One molecule, several targets!
Multispecific Nanofitin assemblies for modulating the tumor microenvironment @ PEGS Europe 2020

Digital, November 2020

Many efforts have been devoted in recent years towards reconditioning the tumor microenvironment to mount an immune response against the tumor. While holding promises, our understanding of the manipulation of the immune system remains limited and has to be addressed with other technical challenges, such as tumor penetration, off-target systemic toxicity, and simultaneous co-engagement of several tumor progression pathways. We will be sharing our strategy to answer these different challenges using the Nanofitin scaffold, with examples of multispecific constructions directed against several tumor progression pathways (angiogenesis, T cell population, and macrophage differentiation).

Multispecific Nanofitin assemblies for modulating the tumor microenvironment